What Is Peptide Therapy?

A Plain-English Guide From Our Coeur d’Alene Medical Team

You feel 38 in your head. But somewhere around 44, your body started sending a different message.

Maybe it’s the sleep that never quite restores you. The energy that stalls out by 2pm regardless of how well you ate. The recovery that takes two days now instead of one. Or the body composition changes that are happening despite the workouts and the protein intake and the discipline you’ve maintained for years.

You’ve probably heard the word “peptide” more than once — from a podcast, a friend, or an Instagram ad that promises results faster than that’s possible. Most of what’s online about peptide therapy is either breathless hype or impenetrable science. What’s missing is someone who actually sees patients, who reads the literature, and who will give you a straight answer about what these compounds can and can’t do.

That’s what this guide is. At Renew, we approach peptide therapy the same way we approach everything else: clinically, honestly, and with your specific labs and goals in front of us — not a product menu. In this article, we’ll explain what peptides are, how they work, what the research actually supports, and what it looks like to explore this at Renew.

A peptide is a short chain of amino acids — the same building blocks that make up proteins. The difference is size: proteins are long, complex chains; peptides are smaller, more targeted messengers.

Your body already produces thousands of them naturally. They function like text messages to your cells — short, specific instructions that tell a tissue, gland, or organ to do something. Release more growth hormone. Repair this damaged tendon. Regulate appetite. Improve blood sugar response.

Therapeutic peptides either mimic naturally occurring peptides your body already makes, or they amplify a process your body does on its own — just less efficiently as you age.

One clarification that comes up constantly: peptides are not steroids. Anabolic steroids are synthetic hormones that flood your system with androgen signals, suppressing your own hormonal feedback loops in the process. Most therapeutic peptides work in a fundamentally different way — by signaling your body to produce and regulate its own hormones more effectively. The regulatory categories, mechanisms, and risk profiles are entirely different.

Most peptides used clinically fall into two broad categories.

Direct-acting peptides bind to receptors in your body and directly trigger a response. GLP-1 receptor agonists like semaglutide (Ozempic®, Wegovy®) and tirzepatide (Mounjaro®, Zepbound®) are the most well-studied examples. They bind to receptors in the gut, pancreas, and brain that regulate blood sugar, insulin response, and satiety — mimicking the natural GLP-1 hormone your body releases after a meal, but with a longer duration of action.

Secretagogues (seh-KREE-tuh-goges — “compounds that stimulate secretion”) work differently. Rather than replacing a hormone, they signal your pituitary gland to produce more of your own. Sermorelin and ipamorelin/CJC-1295 are growth hormone secretagogues that many providers prefer in anti-aging and body composition contexts precisely because they work with your existing hormonal feedback loops rather than bypassing them.

Both approaches involve subcutaneous injection — a small insulin-gauge needle, typically into the abdomen or thigh, usually self-administered at home. If that sounds intimidating, it rarely is in practice. We walk every patient through technique in the office, and most describe the process as very manageable by their second dose.

Patients come to us about peptide therapy for different reasons, and the right protocol depends entirely on what those goals are.

Weight management and metabolic health is the most common conversation right now, driven largely by the FDA-approved GLP-1 class. Semaglutide (available as Ozempic® for type 2 diabetes and Wegovy® for chronic weight management) and tirzepatide (Mounjaro® for diabetes, Zepbound® for weight loss) have reshaped what’s possible in medically supervised weight management. We’ll address the evidence below — it’s compelling, but these medications come with a full clinical picture to understand.

Energy, sleep, and body composition is where growth hormone secretagogues like sermorelin and the ipamorelin/CJC-1295 combination often come in. Growth hormone declines approximately 14% per decade after your 20s. Many patients seeking these compounds aren’t deficient in a clinical sense — but they notice the gradual change and want to address it with something more targeted than lifestyle optimization alone.

Recovery and tissue health. BPC-157 — “Body Protective Compound” — has generated significant interest for tendon, ligament, and gut tissue repair. We’d be doing you a disservice if we didn’t note here: as of mid-2026, BPC-157 is under active FDA review as part of the Category 2 compounding assessment, with a scheduled Pharmacy Compounding Advisory Committee evaluation in July 2026. Its availability through licensed compounding pharmacies may change. We’ll always tell you where things stand before recommending anything.

We believe in telling you what’s established, what’s preliminary, and where we simply don’t have enough data yet.

GLP-1 and GIP/GLP-1 agonists have the strongest evidence base of any peptides in clinical use today. The STEP 1 trial, published in the New England Journal of Medicine, found that semaglutide produced an average body weight reduction of 14.9% over 68 weeks in adults with obesity. The SURMOUNT-1 trial for tirzepatide showed even larger effects — up to 20.9% body weight reduction — with comparable safety profiles. These are the largest weight-loss results ever recorded in a pharmaceutical trial. What the trials also showed: these medications work best alongside behavioral support, and a significant portion of weight tends to return if the medication is stopped without sustainable lifestyle changes in place.

Sermorelin and growth hormone secretagogues have a meaningful but more modest body of evidence. Sermorelin has been in clinical use since FDA approval in 1990 for pediatric growth hormone deficiency. In adults, peer-reviewed studies have demonstrated improvements in IGF-1 levels, lean mass, and sleep quality, though most trials are small and shorter-term than the GLP-1 literature. Research in the Journal of Clinical Endocrinology & Metabolism and others supports the mechanism; the long-term evidence in healthy aging adults is still accumulating.

BPC-157 and some other compounded peptides remain primarily at the animal-study stage. The tissue-repair and gut-health data in rodent models is interesting enough that researchers are pursuing human trials — but as of this writing, we don’t have large-scale peer-reviewed human data. We’ll be direct about that in consultation.

People who tend to be good candidates

•       Adults generally 35 and older experiencing changes in energy, weight, sleep, body composition, or sexual health that haven’t responded adequately to lifestyle optimization alone

•       Those with lab values that confirm a relevant hormonal or metabolic imbalance

•       People with realistic expectations about timeline — meaningful change typically requires 8–16 weeks of consistent treatment

•       Those prepared to pair peptide therapy with the basics: adequate sleep, protein intake, regular movement

Who should have additional evaluation — or may not be candidates

Peptide therapy is not appropriate for everyone, and at Renew, we’re not interested in putting you on a protocol that isn’t right for your health picture. This conversation is essential if you have:

•       Pregnancy or plans to become pregnant, or breastfeeding — peptide therapy is not appropriate during this period

•       Active or recent cancer history — particularly relevant for growth hormone secretagogues; requires physician-level clearance

•       Autoimmune disease, particularly during active flares

•       Uncontrolled type 2 diabetes or cardiovascular disease — may be contraindicated depending on the protocol and must involve your managing physician

Our process is deliberate because it has to be. Here’s what it looks like from your first conversation to your follow-up.

Consultation. We sit down and talk through your symptoms, goals, health history, and any medications or supplements you’re currently taking. This isn’t a rushed intake — we want to understand the full picture before suggesting anything.

Bloodwork. Baseline labs give us the data to design a protocol that’s calibrated to you, not an average patient. Depending on the discussion, this may include IGF-1, metabolic panel, hormone levels, thyroid markers, and CBC.

Personalized protocol. Our medical team designs your protocol based on your labs and goals — not a standard offering. Appropriate dosing and frequency is always individualized by your prescribing clinician.

Injection training. If your protocol includes self-administered subcutaneous injections, we teach you in the office and make sure you feel confident before you go home.

Follow-up and labs. We check in at 8–12 weeks with labs and a symptom review. Protocols are adjusted from there. This isn’t a set-it-and-forget-it approach.

Most patients begin to notice early changes — improved sleep, subtle energy shifts — within the first 2–4 weeks. Meaningful, measurable changes in body composition, IGF-1 levels, or other objective markers typically emerge at 8–16 weeks. We’ll tell you honestly what to watch for and when to expect it.

Commonly reported and generally mild:

•       GLP-1 agonists: nausea, decreased appetite, constipation or loose stools — most patients report these diminish significantly after the first 4–6 weeks as dose is titrated gradually

•       Growth hormone secretagogues: mild water retention early on, occasional headache or fatigue in the first weeks, vivid dreams (actually a marker of improved deep sleep for many patients)

•       PT-141: transient facial flushing, mild nausea

 

Less common: Elevated blood glucose (monitor with GLP-1s in patients with metabolic history), injection site irritation.

We monitor with baseline and follow-up labs, track symptoms at each check-in, and adjust protocols accordingly. Peptide therapy, when prescribed and monitored by a licensed clinician who knows your health history, has a well-documented safety profile. The risk lives in unmonitored, unsupervised use — including the gray-market “research peptide” market, where compounds have no sterility verification, no identity testing, and no legal basis for human use.

Compounded peptides — sermorelin, ipamorelin/CJC-1295, PT-141, and others — are generally not covered by health insurance, as they’re prescribed off-label. FDA-approved GLP-1 medications (Wegovy®, Zepbound®) may carry partial insurance coverage depending on your diagnosis and plan, though coverage has been inconsistent; we’ll help you understand your options.

For specific pricing at Renew, the best path is a consultation — peptide protocols are individualized, and pricing reflects your specific protocol. Contact us at (208) 930-6823 or visit renewcda.com to schedule.

A note on buying peptides online: the gray-market “research peptide” space operates outside pharmaceutical regulations. Products sold there have no sterility verification, no identity testing, and are not legal for human use. This is where real risk lives, and it’s not something we’re able to endorse or monitor. Renew sources only through licensed compounding pharmacies.

Are peptides the same as steroids?

No. Anabolic steroids are synthetic androgens that suppress your body’s own hormone production. Most therapeutic peptides work by signaling your body to produce and regulate its own hormones — a fundamentally different mechanism. They’re in different regulatory categories and carry different risk profiles.

How long until I notice results?

It depends on the peptide and the goal. Some patients notice improved sleep quality or subtle energy changes within 2–4 weeks on growth hormone secretagogues. Meaningful changes in body composition, IGF-1 levels, or metabolic markers typically take 8–16 weeks of consistent use. GLP-1 appetite effects often become noticeable within the first few weeks as dose escalates.

Do I have to inject myself?

Most therapeutic peptides are administered via subcutaneous injection — a small insulin-gauge needle, typically into the abdomen. It’s much less daunting than it sounds. We teach injection technique at your appointment, and the vast majority of patients find it straightforward within a day or two of starting.

Are peptides FDA-approved?

Some are. Semaglutide (Ozempic®, Wegovy®), tirzepatide (Mounjaro®, Zepbound®), and Vyleesi® (PT-141 for women) are FDA-approved drugs with specific approved indications. Many other peptides used in clinical practice — sermorelin, ipamorelin/CJC-1295 — are prescribed off-label and dispensed through licensed compounding pharmacies. Off-label prescribing is legal, common in medicine, and explained fully at your consultation.

What happens if I stop?

It depends on the peptide and whether lifestyle habits are in place. GLP-1 appetite suppression diminishes once the medication is stopped, and research shows most of the weight lost returns within a year without continued medication or strong behavioral anchors. Growth hormone secretagogue benefits in body composition tend to hold better when sleep, protein intake, and resistance training remain consistent. We discuss long-term strategy with every patient.

Can I combine peptide therapy with IV infusions or hormone therapy at Renew?

Often yes — in fact, this is exactly how Renew approaches whole-body wellness. Peptide therapy, IV infusions, and hormone optimization can complement each other meaningfully. Protocol design considers everything you’re doing currently to avoid interactions and maximize results.

Peptide therapy isn’t a single treatment — it’s a category of highly targeted compounds, each with its own evidence base, regulatory status, and ideal patient profile. The GLP-1 class has produced the most significant clinical weight-loss data ever recorded. Growth hormone secretagogues have a meaningful track record in anti-aging and body composition contexts. And research in other areas continues to evolve.

What makes the difference isn’t the peptide itself — it’s whether the protocol is built around your labs, your health history, and your actual goals, by someone with the clinical training to do it responsibly.

If you’d like to explore whether peptide therapy fits your situation, we’d love to have that conversation. Peptide therapy isn’t right for everyone — and the only honest way to know is to sit down with a clinician who can look at your full picture. Book a complimentary consultation at renewcda.com or call us at (208) 930-6823. We’ll give you a candid read before you commit to anything.

Disclaimer

This article is for educational purposes only and is not a substitute for medical advice, diagnosis, or treatment. Peptide therapies discussed may include compounded medications prescribed off-label; off-label prescribing is legal and common in medicine but means the FDA has not specifically approved the medication for the use described. Outcomes vary. The regulatory status of compounded peptides — including BPC-157, ipamorelin/CJC-1295, and others — is subject to change; verify current status with your provider at the time of consultation. Speak with a licensed clinician about your individual health history before starting any peptide protocol. Last medically reviewed: June 2026 by Angela, RN.

Citations

1.     Wilding JPH, et al. “Once-Weekly Semaglutide in Adults with Overweight or Obesity.” New England Journal of Medicine. 2021. STEP 1 Trial. https://pubmed.ncbi.nlm.nih.gov/33567185/

2.     Jastreboff AM, et al. “Tirzepatide Once Weekly for the Treatment of Obesity.” New England Journal of Medicine. 2022. SURMOUNT-1 Trial. https://pubmed.ncbi.nlm.nih.gov/35658024/

3.     Ishida J, et al. “Growth hormone secretagogues: history, mechanism of action, and clinical development.” JCSM Rapid Communications. 2020. https://onlinelibrary.wiley.com/doi/full/10.1002/rco2.9

4.     FDA. Bremelanotide (Vyleesi) Prescribing Information. https://www.fda.gov/drugs/drug-approvals-and-databases/drug-trials-snapshots-vyleesi

5.     FDA. Pharmacy Compounding Advisory Committee — July 2026 Meeting Materials. https://www.fda.gov/advisory-committees/pharmacy-compounding-advisory-committee

6.     Sigalos JT, Pastuszak AW. “The Safety and Efficacy of Growth Hormone Secretagogues.” Sexual Medicine Reviews. 2018. https://pubmed.ncbi.nlm.nih.gov/29117927/

7.     FDA. Tesamorelin (Egrifta) Prescribing Information. https://www.accessdata.fda.gov/drugsatfda_docs/label/2010/022505lbl.pdf